| Phase 12 trials |
|
Phase 1
|
NCT07364214 |
Feb → Apr 2026 |
— |
Arcus Biosciences, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04104672 |
Nov 2019 → May 2027 expected |
malignant exocrine pancreas neoplasm |
Arcus Biosciences, Inc. |
Active not recruiting
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT07667335 |
Dec 2026 → Jul 2029 expected |
infiltrating urothelial carcinoma, urinary bladder carcinoma, urothelial carcinoma |
Fred Hutchinson Cancer Center |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05688215 |
Mar 2023 → Dec 2026 expected |
pancreatic ductal adenocarcinoma |
Jonsson Comprehensive Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04660812 |
May 2021 → Sep 2025 |
colorectal cancer |
Arcus Biosciences, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT04381832 |
Jul 2020 → Aug 2024 |
castration-resistant prostate carcinoma |
Arcus Biosciences, Inc. |
Completed
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT06048484 |
May 2024 → Apr 2027 expected |
pancreatic ductal adenocarcinoma |
Gulam Manji |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06048133 |
Mar 2024 → Jul 2026 overdue |
cholangiocarcinoma |
Nataliya Uboha |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05915442 |
Jul 2023 → Dec 2026 expected |
metastatic prostate carcinoma |
Catherine Spina |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05676931 |
Feb 2023 → Dec 2027 expected |
non-small cell lung carcinoma |
Gilead Sciences |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05329766 |
Jun 2022 → Jan 2027 expected |
digestive system cancer |
Arcus Biosciences, Inc. |
Active not recruiting
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT06608927 |
Dec 2024 → Nov 2030 expected |
pancreatic ductal adenocarcinoma |
Arcus Biosciences, Inc. |
Active not recruiting
|
No outcome recorded
|